# Sacituzumab tirumotecan PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sacituzumab-tirumotecan

> The next catalyst for sacituzumab tirumotecan, sponsored by Merck & Co., Inc. (MRK), is its topline data readout, May to Aug 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | sacituzumab tirumotecan |
| Codes | MK-2870, SKB264 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [non-small cell lung cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer), [Bladder Cancer](https://sec-api.dev/indications/bladder-cancer), [Cervical Cancer](https://sec-api.dev/indications/cervical-cancer), [Non-small Cell Lung Cancer (NSCLC)](https://sec-api.dev/indications/non-small-cell-lung-cancer-nsclc), [Gastroesophageal Cancer](https://sec-api.dev/indications/gastroesophageal-cancer), [Ovarian Cancer](https://sec-api.dev/indications/ovarian-cancer), [Endometrial Cancer](https://sec-api.dev/indications/endometrial-cancer) |
| Modality | adc |
| FDA designations | breakthrough, priority review |

## Timeline

### October 19, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Gastroesophageal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06356311 (A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06356311

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Gastroesophageal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06356311 (A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06356311

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06074588 (Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06074588

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06074588 (Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06074588

### 2H 2027: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1/2. Indication: non-small cell lung cancer.
- First seen 2026-07-30, last confirmed 2026-11-12.
- SEC Form 10-Q (accession 0001628280-26-073389): "We also initiated a global Phase 1/2 trial of CR-002 (the "APOLLO trial") in the fourth quarter of 2026, with initial data expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1253689/000162828026073389/cbio-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-073409): "Multiple Phase 2 studies of sacituzumab tirumotecan (sac-TMT) in combination with CR-001 ongoing in China led by partner, Kelun-Biotech, with initial data in NSCLC expected in mid-2027; additional antibody-drug conjugate (ADC) combinations planned; partnership achieved 9 IND clearances this year" https://www.sec.gov/Archives/edgar/data/1253689/000162828026073409/pressrelease-livefile.htm
- SEC Form 10-Q (accession 0001628280-26-073389): "Additionally, Kelun initiated multiple Phase 2 clinical studies in China of its trophoblast cell-surface antigen 2 (TROP2)-directed ADC sacituzumab tirumotecan ("sac-TMT") in combination with CR-001 to evaluate the safety, tolerability, and efficacy in patients with non-small cell lung cancer ("NSCLC") and other solid tumors, with initial data from NSCLC patients anticipated in mid-2027 (second or third quarter)." https://www.sec.gov/Archives/edgar/data/1253689/000162828026073389/cbio-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-050869): "Additionally, Kelun recently initiated a Phase 2 clinical study in China of its trophoblast cell-surface antigen 2 (TROP2)-directed ADC sacituzumab tirumotecan ("sac-TMT") in combination with CR-001 to evaluate the safety, tolerability, and efficacy of patients with non-small cell lung cancer ("NSCLC"), with initial data anticipated in mid-2027 (second or third quarter)." https://www.sec.gov/Archives/edgar/data/1253689/000162828026050869/cbio-20260630.htm

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Endometrial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06132958 (Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06132958

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Endometrial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06132958 (Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06132958

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Cervical Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06459180 (A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06459180

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Cervical Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06459180 (A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06459180

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06305754 (Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06305754

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06305754 (Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06305754

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06824467 (A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06824467

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06824467 (A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06824467

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Bladder Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07419295 (A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07419295

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Bladder Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07419295 (A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07419295

## Same indication

- [Bnt323/db-1303](https://sec-api.dev/pdufa/bnt323-db-1303) (BNTX)
- [Datopotamab deruxtecan (dato-dxd)](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) (AZN)
- [INCB123667](https://sec-api.dev/pdufa/incb123667) (INCY)
- [Amtagvi® (lifileucel)](https://sec-api.dev/pdufa/lifileucel) (IOVA)
- [Luveltamab tazevibulin](https://sec-api.dev/pdufa/luveltamab-tazevibulin) (STRO)
- [Mirvetuximab soravtansine](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) (ABBV)
- [Mirvetuximab soravtansine plus bevacizumab](https://sec-api.dev/pdufa/mirvetuximab-soravtansine-plus-bevacizumab) (ABBV)
- [LYNPARZA® (olaparib)](https://sec-api.dev/pdufa/olaparib) (AZN)
- [Pamiparib capsule](https://sec-api.dev/pdufa/pamiparib) (ONC)
- [Pemazyre (pemigatinib)](https://sec-api.dev/pdufa/pemigatinib) (INCY)
- [Prgn-2009 plus pembrolizumab](https://sec-api.dev/pdufa/prgn-2009-plus-pembrolizumab) (PGEN)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)
- [Puxitatug samrotecan](https://sec-api.dev/pdufa/puxitatug-samrotecan) (AZN)
- [REGN10597](https://sec-api.dev/pdufa/regn10597) (REGN)
- [Lifyorli™ (relacorilant)](https://sec-api.dev/pdufa/relacorilant) (CORT)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)
- [Sacituzumab govitecan-hziy](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) (GILD)
- [Sapanisertib](https://sec-api.dev/pdufa/sapanisertib) (FTH)
- [IBTROZI (taletrectinib)](https://sec-api.dev/pdufa/taletrectinib) (NUVB)
- [TAR-200](https://sec-api.dev/pdufa/tar-200) (JNJ)
- [ENHERTU (trastuzumab deruxtecan)](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) (AZN)
- [UGN-103](https://sec-api.dev/pdufa/ugn-103) (URGN)
- [Vudalimab](https://sec-api.dev/pdufa/vudalimab) (XNCR)

Calendar months: [May 2027](https://sec-api.dev/fda-calendar/2027-05), [January 2028](https://sec-api.dev/fda-calendar/2028-01), [June 2028](https://sec-api.dev/fda-calendar/2028-06), [August 2028](https://sec-api.dev/fda-calendar/2028-08)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sacituzumab-tirumotecan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sacituzumab tirumotecan PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sacituzumab-tirumotecan

```bibtex
@misc{secapidev_pdufa_sacituzumab_tirumotecan_20261116,
  title        = {Sacituzumab tirumotecan PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sacituzumab-tirumotecan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sacituzumab_tirumotecan_20261116","title":"Sacituzumab tirumotecan PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sacituzumab-tirumotecan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
